One of the masterminds behind remdesivir, Gilead's Diana Brainard jumps ship to antiviral T cell player AlloVir

Kyle Blankenship

As one of the startups tapped to join David Hallal’s disruptive manufacturing outfit ElevateBio in the Boston area, AlloVir has built an aggressive clinical program …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

One of the masterminds behind remdesivir, Gilead's Diana Brainard jumps ship to antiviral T cell player AlloVir

Kyle Blankenship

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

One of the mas­ter­minds be­hind remde­sivir, Gilead­'s Di­ana Brainard jumps ship to an­tivi­ral T cell play­er AlloVir

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

One of the masterminds behind remdesivir, Gilead's Diana Brainard jumps ship to antiviral T cell player AlloVir